<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190916044784N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-05-25</date_registration>
      <primary_sponsor>Khoram-Abad University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of Ondansetron and Dexamethasone Versus Dexamethasone efficacy On Postoperative nausea and vomiting in patients with maxillofacial trauma refered to "Shohadaye Ashayer" hospital of Khorramabad</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of Ondansetron and Dexamethasone Versus Dexamethasone efficacy On Postoperative nausea and vomiting in patients with maxillofacial trauma</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>96</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/63054</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Education/Guidance, Randomization description: In order to equalize the production of individuals in the two groups, the Block Randomization method is used. Using this method, the sample size in the two study arms will be equal (balance), Blinding description: In order to blind the study, the severity of postoperative nausea and vomiting of patients is assessed by a person who is not aware of the study groups. Also, the patient and the person analyzing the study information are not aware of the drug injected for each patient.</study_design>
      <phase>3</phase>
      <hc_freetext>Maxillofacial trauma.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Intervention group: For all the studied patients, after entering the operating room (both the intervention group and the control group), an IV line will be installed. In order to prevent dehydration of patients, 500 cc of Ringer's serum is injected for each patient. Then, for all patients, pre-medication with midazolam in the amount of 2-3 mg and narcotic (fentanyl) in the amount of 2-4 cc (depending on the weight of the people) is done. After 3-5 minutes, induction of anesthesia begins. In all patients, propofol at the rate of 2-2.5 mg/kg, and atrocurium at the rate of 2.5 mg/kg as a muscle relaxant are used to induce anesthesia. Before surgery and during induction of anesthesia, 8 mg of dexamethasone is injected as an IV injection for all patients (whether in the intervention or control group). All subjects undergo nasal intubation 2-4 minutes after induction of anesthesia and injection of relaxant. After intubation, all people are connected to a mechanical ventilator. During surgery, anesthesia is maintained in all patients through TIVA and propofol will be injected at the rate of 0.1 mg/kg/minute. During the surgery, depending on the patient's needs (once every 35-45 minutes), the muscle relaxant will be repeated at the rate of 0.2 mg/kg. All patients are transferred to the recovery room after surgery, and the amount of nausea and vomiting as well as their possible side effects are recorded at intervals of 1, 2, 6, 12 and 24 hours after surgery. At the end of surgery, 8 mg of ondansetron is injected through IV injection for the intervention group. Intervention 2: Control group: For the control group, no medicine is prescribed in addition to what was proposed as the main study protocol. After surgery, dexamethasone is injected for all patients on the first day at the rate of 2 doses per day and on the second day at the rate of 1 dose per day. In order to prevent disturbances in the treatment process of the patients, if nausea and vomiting of any of the patients (including from intervention and control group) was higher than one level, intervention and drug administration will be done to reduce or eliminate nausea and vomiting. This topic will be recorded in the questionnaire and study information.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Kosar Rostampur</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Zomorrod 1 Apartment , Arasteh 6 Ave., Enghelab Blvd.</address>
        <city>Khorramabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6816844168</zip>
        <telephone>+98 66 3321 8502</telephone>
        <email>kosar_rostampur@yahoo.com</email>
        <affiliation>Khoram-Abad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Kosar Rostampur</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Zomorrod 1 Apartment , Arasteh 6 Ave., Enghelab Blvd.</address>
        <city>Khorramabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6816844168</zip>
        <telephone>+98 66 3321 8502</telephone>
        <email>kosar_rostampur@yahoo.com</email>
        <affiliation>Khoram-Abad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>All patients referred to the "Shohadaye Ashayer" Hospital who have maxillofacial trauma and require surgery under general anesthesia.</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients who underwent another operation under general anesthesia 24 hours before maxillofacial surgery.
Patients who have lost consciousness for any reason after trauma.
Patients with ASA≥III.
Patients with a history of Motion sickness or recent vomiting.
Patients who have severe hypotension and bradycardia while surgery, and need intraoperative blood transfusion or postoperative ICU.
Patients with hypersensitivity or allergy to any of the studied drugs.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>S02</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Fracture of skull and facial bones</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Intervention group: For all the studied patients, after entering the operating room (both the intervention group and the control group), an IV line will be installed. In order to prevent dehydration of patients, 500 cc of Ringer's serum is injected for each patient. Then, for all patients, pre-medication with midazolam in the amount of 2-3 mg and narcotic (fentanyl) in the amount of 2-4 cc (depending on the weight of the people) is done. After 3-5 minutes, induction of anesthesia begins. In all patients, propofol at the rate of 2-2.5 mg/kg, and atrocurium at the rate of 2.5 mg/kg as a muscle relaxant are used to induce anesthesia. Before surgery and during induction of anesthesia, 8 mg of dexamethasone is injected as an IV injection for all patients (whether in the intervention or control group). All subjects undergo nasal intubation 2-4 minutes after induction of anesthesia and injection of relaxant. After intubation, all people are connected to a mechanical ventilator. During surgery, anesthesia is maintained in all patients through TIVA and propofol will be injected at the rate of 0.1 mg/kg/minute. During the surgery, depending on the patient's needs (once every 35-45 minutes), the muscle relaxant will be repeated at the rate of 0.2 mg/kg. All patients are transferred to the recovery room after surgery, and the amount of nausea and vomiting as well as their possible side effects are recorded at intervals of 1, 2, 6, 12 and 24 hours after surgery. At the end of surgery, 8 mg of ondansetron is injected through IV injection for the intervention group.</i_keyword>
      <i_keyword>Control group: For the control group, no medicine is prescribed in addition to what was proposed as the main study protocol. After surgery, dexamethasone is injected for all patients on the first day at the rate of 2 doses per day and on the second day at the rate of 1 dose per day. In order to prevent disturbances in the treatment process of the patients, if nausea and vomiting of any of the patients (including from intervention and control group) was higher than one level, intervention and drug administration will be done to reduce or eliminate nausea and vomiting. This topic will be recorded in the questionnaire and study information.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Nausea and vomiting. Timepoint: 1, 2, 6, 12 and 24 hours after surgery. Method of measurement: Direct questions from patient.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Khoram-Abad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-03-09</approval_date>
        <contact_name>Ethics committee of Lorestan University of Medical Sciences</contact_name>
        <contact_address>Lorestan School of Dentistry, Between Golshan 1,2 Ave., Shafipour Blvd. Khorramabad Lorestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
